Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chi-Ju-Di-Huang-Wan + Jia-Wei-Xiao-Yao-San is a Traditional Chinese Medicine (TCM) combination therapy developed by China Medical University Hospital for the treatment of dry eye disease. The formula consists of two classic TCM preparations: Chi-Ju-Di-Huang-Wan (CJDHW), which typically contains Lycium fruit and Chrysanthemum flower, and Jia-Wei-Xiao-Yao-San (JWXYS), also known as Augmented Rambling Powder. In clinical pilot studies, this combination has been evaluated as an oral complementary therapy alongside artificial tears. Its mechanism of action involves the suppression of inflammatory cytokines and the prevention of vascular endothelial growth factor (VEGF) upregulation in tears, leading to increased tear secretion and reduced ocular surface inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chi-Ju-Di-Huang-Wan + Jia-Wei-Xiao-Yao-San.